Efficacy and safety of albumin infusion for overt hepatic encephalopathy: A systematic review and meta-analysis
In: Digestive and Liver Disease, Jg. 53 (2021-07-01), S. 817-823
Online
unknown
Zugriff:
Background and Aims The efficacy and safety of albumin infusion for treatment and prevention of overt hepatic encephalopathy (OHE) among cirrhosis patients remained controversial. We performed a systematic review and meta-analysis to evaluate the benefit of albumin infusion for the treatment and prevention of OHE. Methods We performed a systematic search of 4 electronic databases up to 31st January 2021. The primary outcome was the resolution of OHE. Secondary outcomes were inpatient mortality and albumin-associated adverse events. We assessed the pooled odds’ risk, pooled mean differences, 95% confidence interval and heterogeneity using Review Manager Version 5.3. Results A total of 12 studies (2,087 subjects) were identified. Among cirrhosis patients with OHE, albumin infusion was associated with a lower pooled risk of OHE (OR=0.43, 95%CI: 0.27, 0.68; I2=0%). Among patients without baseline OHE, albumin infusion was associated with a lower pooled risk of developing OHE (OR=0.53, 95%CI: 0.32, 0.86; I2=62%). Albumin infusion was associated with a lower pooled risk of inpatient mortality (OR=0.36, 95%CI: 0.21, 0.60; I2=0%). Conclusion Well-powered randomized trials are required to confirm the benefits of albumin infusion for the prevention and treatment of overt hepatic encephalopathy among decompensated cirrhosis patients.
Titel: |
Efficacy and safety of albumin infusion for overt hepatic encephalopathy: A systematic review and meta-analysis
|
---|---|
Autor/in / Beteiligte Person: | Yew Chong Tam ; Yu Jun Wong ; Jing Hong Loo ; Kok Ban Teh |
Link: | |
Zeitschrift: | Digestive and Liver Disease, Jg. 53 (2021-07-01), S. 817-823 |
Veröffentlichung: | Elsevier BV, 2021 |
Medientyp: | unknown |
ISSN: | 1590-8658 (print) |
DOI: | 10.1016/j.dld.2021.04.030 |
Schlagwort: |
|
Sonstiges: |
|